PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Launchpiperacillin and tazobactam and sodium chloride
NDAINTRAVENOUSPOWDER
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER (piperacillin and tazobactam and sodium chloride) by B. Braun is 12. Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Piperacillin/tazobactam with sodium chloride in a duplex container is a combination beta-lactam/beta-lactamase inhibitor antibiotic administered intravenously. It treats serious infections including nosocomial pneumonia, intra-abdominal infections, skin infections, and pelvic inflammatory disease caused by beta-lactamase producing organisms. The drug works by inhibiting bacterial cell wall synthesis while tazobactam protects piperacillin from enzymatic degradation.
Launch
Recently approved formulation entering market with growth potential; B. Braun likely establishing dedicated launch team with focused commercial infrastructure.
Mechanism of Action
12.1 Mechanism of Action Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is an antibacterial drug [see ]. 12.2 Pharmacodynamics The pharmacodynamic parameter for piperacillin and tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC.…
Worked on PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.